ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 157 filers reported holding ASCENDIS PHARMA A/S in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $772,000 | +63.6% | 5,000 | +19.2% | 0.21% | +18.3% |
| Q1 2020 | $472,000 | -32.2% | 4,195 | -16.1% | 0.18% | +63.6% |
| Q4 2019 | $696,000 | -27.7% | 5,000 | -50.0% | 0.11% | -20.1% |
| Q3 2019 | $963,000 | -16.4% | 10,000 | 0.0% | 0.13% | 0.0% |
| Q2 2019 | $1,152,000 | -2.1% | 10,000 | 0.0% | 0.13% | +38.1% |
| Q1 2019 | $1,177,000 | +87.7% | 10,000 | 0.0% | 0.10% | +83.0% |
| Q4 2018 | $627,000 | -11.6% | 10,000 | 0.0% | 0.05% | +17.8% |
| Q3 2018 | $709,000 | +6.6% | 10,000 | 0.0% | 0.04% | +4.7% |
| Q2 2018 | $665,000 | – | 10,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |